MTOR and ovarian carcinoma: In addition, treatment with baicalein increased the expression of DDIT4 (a negative regulator of mTOR), enhanced AMPK phosphorylation, and reduced phosphorylation of downstream effectors S6K1 and S6, consistent with prior studies in breast and ovarian cancer.